The latest report from Acumen Research And Consulting highlights that the global Compound Management Market is on a strong ...

Global 3D Cell Culture Market OverviewThe global 3D cell culture market is projected to register a strong double-digit growth rate by 2031, driven by the rapid evolution of life science research and ...

The global pulse oximeter market is expected to expand at a compound annual growth rate (CAGR) of approximately 7% over the forecast period. Market growth is primarily driven by the rising incidence ...

The global vaccine Contract Development and Manufacturing Organization (CDMO) market is projected to expand at a compound ...

Global Cold Plasma Market OverviewThe global cold plasma market is projected to grow at a robust compound annual growth rate of nearly 16% during the forecast period from 2026 to 2031, driven by its ...

Dental 3D Printing MarketThe dental 3D printing market is witnessing robust growth, with an anticipated compound annual growth rate (CAGR) of approximately 20% over the forecast period. This expansion ...

Market OverviewThe global transrectal ultrasound (TRUS) market is experiencing consistent expansion and is projected to grow at a compound annual growth rate of around 6% during the forecast period.

Ardena completes divestment of its Södertälje drug substance site in Sweden to NanologicaGhent, Belgium, 29th January 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision ...

M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative diseaseNEEDHAM, MASS., Jan 29, 2026 - (ACN Newswire) — Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” ...

The global antibody testing market is expected to expand at a compound annual growth rate (CAGR) of approximately 6% between 2025 and 2030. This growth is primarily driven by the increasing burden of ...

MMS, a global, data-focused clinical research organization (CRO), today announced it has been named a finalist in the 2026 ...

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to ...